First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021- WALTHAM, MA- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, announced today they have partnered with...
Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. – DECEMBER 7, 2020Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today...
Dimitrios A. Pappas, Christine Brittle, James E. Mossell III, Johanna B. Withers, Jeraldine Lim-Harashima & Joel M. Kremer Rheumatology International volume 41, pages585–593 (2021) Abstract: Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease...
PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory.Partnership provides infrastructure for rapid scaling and patient accessibility. SEPTEMBER 17, 2020- WALTHAM, MA, and ALISO VIEJO, CA – Scipher Medicine, a precision...
AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLCAlif Saleh, CEO, Scipher Medicine Drug costs for targeted autoimmune diseases account for a large and growing proportion of pharmacy spend per patient. Despite...
Martin J. Bergman, Alan J. Kivitz, Dimitrios A. Pappas, Joel M. Kremer, Lixia Zhang, Anna Jeter & Johanna B. Withers Rheumatology and Therapy volume 7, pages775–792 (2020) Abstract: Introduction: The PrismRA® test identifies rheumatoid arthritis (RA) patients who...
— Companies to jointly validate novel drug targets —- Scipher eligible for upfront, opt-in and milestone payments —- Galapagos to progress selected targets into drug discovery — Mechelen, Belgium and Boston, USA; 12 August 2020 –...
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine, a precision immunology company that helps match patients with their most effective therapy, today announced successful results...
Theodore Mellors, Johanna B. Withers, Asher Ameli, Alex Jones, Mengran Wang, Lixia Zhang, Helia N. Sanchez, Marc Santolini, Italo Do Valle, Michael Sebek, Feixiong Cheng, Dimitrios A. Pappas, Joel M. Kremer, Jeffery R. Curtis, Keith J. Johnson, Alif Saleh, Susan D....
The Lancet The ongoing COVID-19 pandemic has motivated many across the globe to adopt different approaches to understand the virus, surveil how the virus spreads, and search for effective treatments. This health crisis has focused global efforts on leveraging...
Silicon AngleR. Danes Is investor belt-tightening brought on by COVID-19 the bitter medicine needed to bring sanity to the artificial intelligence funding bubble, flush out fakes, and shift venture capitalists’ attention to the most deserving companies? In...
BBCJane Wakefield, Technology Reporter Normally, just getting them all to work together would take “a year of paperwork”, said Scipher’s chief executive Alif Saleh. But a series of Zoom calls with a “group of people with a unprecedented...
Optum Ventures is among companies investing $25 million, betting on the company’s ability to show for which patients Humira doesn’t work. Healthcare Finance NewsSusan Morse, Managing Editor Humira is the top-selling prescription drug by revenue....
Appoints Slava Akmaev, Ph.D., as Chief Technology Officer WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed most effective therapy, today announces the addition of Slava...
Investment to Accelerate Molecular Diagnostic Product Selection, Development and Accessibility WALTHAM (February 19, 2020) — Scipher Medicine, a developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy, announced...
